21.02.2012 • News

Huntsman Posts Higher Q4 Profit

Chemicals maker Huntsman fourth-quarter profit narrowly beat Wall Street's expectations, helped by higher prices for chemicals used to make insulation and paint.

For the quarter, the company posted net income of $105 million, or 44 cents per share, compared with $30 million, or 12 cents per share, a year ago.

Excluding items, Huntsman earned 28 cents a share.

By that measure, analysts expected earnings of 27 cents per share, according to Thomson Reuters I/B/E/S.

"Looking forward, we anticipate that the corporation will see an improving global economy from this point forward," Chief Executive Peter Huntsman said in a statement. "Most of our businesses have strong upside potential as we see a continued recovery in the world's economy."

Revenue rose 9% to $2.63 billion. Analysts expected $2.69 billion in revenue.

The jump in revenue was highest in the polyurethanes unit, which makes products for insulation markets, and the pigments unit, which makes titanium dioxide pigment for paint. Price hikes in both units also lifted results.

DuPont is a large competitor in the titanium dioxide space.

Huntsman's textile effects unit saw sales fall 8% as customers bought fewer specialty clothing materials and due to the high value of the Swiss franc.

The quarterly results are the first since Jon Huntsman Jr., the former U.S. presidential candidate, son of the company's founder and brother to the chief executive, joined the company's board of directors.

 

 

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.